Obinutuzumab for the First-Line Treatment of Follicular Lymphoma - HHM

Open Access Repository for Health care Articles and Medical Researches

Post Top Ad

Your Ad Spot

Thursday, 5 October 2017

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, M.B., B.S., Andrew Davies, B.M., Ph.D., Kiyoshi Ando, M.D., Ph.D., Wolfram Klapper, M.D., Ph.D…

Journal: N Engl J Med 2017; 377:1331-1344

Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody.

In this research rituximab-based chemotherapy was compared with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.

The researchers randomly assigned patients to undergo induction treatment with obinutuzumab-based chemotherapy or rituximab-based chemotherapy.

Patients with a response received maintenance treatment for up to 2 years with the same antibody that they had received in induction. The primary end point was investigator-assessed progression-free survival.

A total of 1202 patients with follicular lymphoma underwent randomization (601 patients in each group).

After a median follow-up of 34.5 months (range, 0 to 54.5), a planned interim analysis showed that Obinutuzumab-based immunochemotherapy and maintenance therapy resulted in longer progression-free survival than rituximab-based therapy. High-grade adverse events were more common with obinutuzumab-based chemotherapy.